drugset / Trial / NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3
Recruiting
440 enrolled
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Celgene Corporation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Timeline
- Start
- 2025-03-12
- Primary completion
- 2027-12-30
- Completion
- 2032-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arlocabtagene Autoleucel | Unknown | — | — |
| Background | Carfilzomib | Other / unclassified | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Daratumumab | Monoclonal antibody | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Pomalidomide | Other / unclassified | — | — |